Accelerator™ Drug Development: Collaborative Timeline Management Drives Speed and Simplicity in Global Vaccine Trial

Coordinating a global Phase III vaccine study across 6,000+ subjects, 170 sites, and 20+ countries presents extraordinary logistical and regulatory challenges from cold-chain distribution to regional labeling and site activation.

Through proactive alignment and coordinated oversight, Thermo Fisher Scientific’s Accelerator™ Drug Development team helped a leading biopharma company overcome these complexities saving five weeks on IMP release and achieving on-time first patient in (FPI) milestones.

By integrating quality, supply, and operational strategies early, Thermo Fisher enabled faster startup, reduced handoffs, and set a new standard for collaborative execution in large-scale vaccine trials.